Literature DB >> 21220206

Incidence and risk factors of oral mucositis in paediatric and adolescent patients undergoing chemotherapy.

Karis Kin Fong Cheng1, Vincent Lee, Chak Ho Li, William Goggins, David R Thompson, Hui Leung Yuen, Joel B Epstein.   

Abstract

There is a dearth of studies with respect to oral mucositis (OM) in the paediatric and adolescent populations. The purpose of this prospective cohort study was to examine the incidence and risk factors associated with OM in paediatric and adolescent patients receiving chemotherapy. OM assessments were made daily until 14days after chemotherapy using the self-report Mouth and Throat Soreness-Related Questions of the Oral Mucositis Daily Questionnaire (OMDQ MTS). Potential risk factors included age, gender, prior OM, anxiety level, cancer diagnosis, nausea/vomiting, use of growth factor, neutrophil count, liver enzymes, and creatinine value. Multiple logistic, Cox proportional hazards, and ordinal regression analyses were used to determine risk factors for the incidence and time to onset of MTS scores of ⩾2, and MTS scores across 14days by AUC categories, respectively, after adjusting for chemotherapy. A total of 140 patients who were 6-18years of age were evaluated. Forty-one percent (95% CI, 32.6-48.8%) developed OM; of these, 23% and 18% reported a maximum MTS score of 2 and 3-4 as the worst OM, respectively. The mean time to onset of OM was 4.7±2.7days with a mean duration of 6.3±4days. Prior OM (RR 1.90-3.94), a higher level of anxiety (RR 1.27-1.46), WHO grade 1-2 (RR 1.86-4.59) and 3-4 (RR 3.08-9.19) neutropenia were significantly associated with a higher probability of the incidence, earlier onset, and greater severity of OM, after controlling for chemotherapy (p<0.01). OM was associated with indirect cytotoxicity, prior OM, and anxiety level after controlling for chemotherapy where neutropenia was found to be the most important factor.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21220206     DOI: 10.1016/j.oraloncology.2010.11.019

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  19 in total

1.  Oral mucositis in pediatric and adolescent patients undergoing chemotherapy: the impact of symptoms on quality of life.

Authors:  Karis Kin Fong Cheng; Vincent Lee; Chak Ho Li; Hui Leung Yuen; Joel B Epstein
Journal:  Support Care Cancer       Date:  2011-12-14       Impact factor: 3.603

2.  Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children? : Results from a prospective multicenter double blind randomized controlled trial.

Authors:  M F Raphael; A M den Boer; W J W Kollen; H Mekelenkamp; F C H Abbink; G J L Kaspers; K Zomer-Kooijker; B H W Molmans; W J E Tissing
Journal:  Support Care Cancer       Date:  2013-11-07       Impact factor: 3.603

3.  Incidence and risk factors for oral mucositis in pediatric patients receiving chemotherapy.

Authors:  Marina Curra; Amanda F Gabriel; Maria Beatriz C Ferreira; Marco Antonio T Martins; André T Brunetto; Lauro J Gregianin; Manoela Domingues Martins
Journal:  Support Care Cancer       Date:  2021-04-12       Impact factor: 3.603

4.  Chemotherapy-induced oral mucositis in children and adolescents: a systematic review.

Authors:  R Docimo; M D Anastasio; C Bensi
Journal:  Eur Arch Paediatr Dent       Date:  2022-07-02

5.  The effectiveness of an oral health education and prevention program on the incidence and severity of oral mucositis in pediatric cancer patients: a non-randomized controlled study.

Authors:  Paula Maria Maracajá Bezerra; Maria Eduarda Alves Sampaio; Fabio Gomes Dos Santos; Isabella Lima Arrais Ribeiro; Bianca Marques Santiago; Simone Alves de Sousa; Ana Maria Gondim Valença
Journal:  Support Care Cancer       Date:  2021-06-29       Impact factor: 3.603

6.  Impact of oral mucositis on short-term clinical outcomes in paediatric and adolescent patients undergoing chemotherapy.

Authors:  Karis Kin Fong Cheng; Vincent Lee; Chak Ho Li; Hui Leung Yuen; Wan Yim Ip; Hong Gu He; Joel B Epstein
Journal:  Support Care Cancer       Date:  2013-03-08       Impact factor: 3.603

7.  Pretherapeutic plasma pro- and anti- inflammatory mediators are related to high risk of oral mucositis in pediatric patients with acute leukemia: a prospective cohort study.

Authors:  Ying Ye; Göran Carlsson; Monica Barr Agholme; Jenny Karlsson-Sjöberg; Tülay Yucel-Lindberg; Katrin Pütsep; Thomas Modéer
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

8.  Oral Mucositis in Pediatric Patients in Treatment for Acute Lymphoblastic Leukemia.

Authors:  Isabella Lima Arrais Ribeiro; Rebecca Rhuanny Tolentino Limeira; Ricardo Dias de Castro; Paulo Rogério Ferreti Bonan; Ana Maria Gondim Valença
Journal:  Int J Environ Res Public Health       Date:  2017-11-28       Impact factor: 3.390

9.  The incidence of severe oral mucositis and its occurrence sites in pediatric oncologic patients.

Authors:  J-R Guimarães; L-G Carvalho; L-C Damascena; M-E Sampaio; I-L Ribeiro; S-A Sousa; A-M Valença
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2021-05-01

Review 10.  Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice.

Authors:  Douglas E Peterson; Joyce A O'Shaughnessy; Hope S Rugo; Sharon Elad; Mark M Schubert; Chi T Viet; Cynthia Campbell-Baird; Jan Hronek; Virginia Seery; Josephine Divers; John Glaspy; Brian L Schmidt; Timothy F Meiller
Journal:  Cancer Med       Date:  2016-06-23       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.